Latest inventory for MYOV: $30M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Myovant Sciences posts a inventory of $30M as of December 2022. That compares with $6.7M in the prior-year period — up 346.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Myovant Sciences's inventory was $6.7M. The latest reading is $30M — a 346.5% year-over-year increase (period ending December 2022). Use the history and growth charts on this page for a longer lookback.
Inventory is one piece of Myovant Sciences's financial statement story. At $30M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for MYOV's inventory usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Myovant Sciences's other metric pages and overview cover the third.
Judging Myovant Sciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in inventory easier to interpret. Start with $30M here, then scan peer and history charts to see if the gap is persistent.